{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T18:51:34Z","timestamp":1781203894101,"version":"3.54.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The optimal antithrombotic therapy to balance the risk of thrombosis and bleeding in patients who undergo transcatheter aortic valve implantation (TAVI) is unknown. This systematic review\/network meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the efficacy and safety of different oral anticoagulant (OAC) and antiplatelet regimens in patients post-TAVI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov were searched from inception to April 2023. Co-primary outcomes were all-cause death and major bleeding. We conducted Bayesian network meta-analyses to compare all interventions simultaneously. For each outcome, we generated odds ratios (ORs) with 95% credible intervals using a random-effects model with informative priors, and ranked interventions based on mean surface under the cumulative ranking curve. We included 11 RCTs (n\u00a0=\u00a06415), including 1 unpublished RCT. Three trials enrolled patients with an indication for an OAC. Overall risk of bias was low or with some concerns. Median age was 81 years. Median follow-up was 6 months. The combination of OAC plus single antiplatelet therapy (SAPT) increased the risk of all-cause death compared with dual antiplatelet therapy (DAPT) (OR 1.78, 95% credible interval 1.15\u20132.77). No other comparisons for all-cause death were significantly different. For major bleeding, SAPT reduced the risk compared with DAPT, direct-acting OAC, and OAC\u00a0+\u00a0SAPT (OR 0.20\u20130.40), and DAPT reduced the risk compared with OAC\u00a0+\u00a0SAPT. SAPT and DAPT ranked best for all-cause death, while SAPT ranked best for major bleeding.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In post-TAVI patients, SAPT may provide the optimal balance of reducing thrombotic events while minimizing the risk of bleeding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvad101","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T07:59:38Z","timestamp":1702108778000},"page":"454-464","source":"Crossref","is-referenced-by-count":13,"title":["Antithrombotic therapy in patients after transcatheter aortic valve implantation: a network meta-analysis"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-1528","authenticated-orcid":false,"given":"Ricky D","family":"Turgeon","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, British Columbia , V6T 1Z3, Canada"},{"name":"St. Paul's Hospital , Vancouver, British Columbia , V6Z 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5896-4852","authenticated-orcid":false,"given":"Ursula M","family":"Ellis","sequence":"additional","affiliation":[{"name":"Woodward Library, University of British Columbia , Vancouver, British Columbia , V6T 1Z3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-898X","authenticated-orcid":false,"given":"Arden R","family":"Barry","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of British Columbia , Vancouver, British Columbia , V6T 1Z3, Canada"},{"name":"Jim Pattison Outpatient Care and Surgery Centre, Lower Mainland Pharmacy Services , Surrey, British Columbia , V3T 0G9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"key":"2024081413471670300_bib1","first-page":"489","article-title":"Aortic stenosis: insights on pathogenesis and clinical implications","volume":"13","author":"Carita","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"2024081413471670300_bib2","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","article-title":"Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery","volume":"363","author":"Leon","year":"2010","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib3","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa1103510","article-title":"Transcatheter versus surgical aortic-valve replacement in high-risk patients","volume":"364","author":"Smith","year":"2011","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib4","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1202277","article-title":"Transcatheter aortic-valve replacement for inoperable severe aortic stenosis","volume":"366","author":"Makkar","year":"2012","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib5","first-page":"e72","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"2024081413471670300_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2024081413471670300_bib7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.cjca.2019.08.011","article-title":"2019 Canadian Cardiovascular Society position statement for transcatheter aortic valve implantation","volume":"35","author":"Asgar","year":"2019","journal-title":"Can J Cardiol"},{"key":"2024081413471670300_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/clc.22426","article-title":"Single vs dual antiplatelet therapy following transcatheter aortic valve implantation: a systematic review","volume":"38","author":"Turgeon","year":"2015","journal-title":"Clin Cardiol"},{"key":"2024081413471670300_bib9","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"2024081413471670300_bib10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jacc.2012.09.001","article-title":"Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document","volume":"60","author":"Kappetein","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2024081413471670300_bib11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Br Med J"},{"key":"2024081413471670300_bib12","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2024081413471670300_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int J Epidemiol"},{"key":"2024081413471670300_bib14","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.amjcard.2011.07.049","article-title":"Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation","volume":"108","author":"Ussia","year":"2011","journal-title":"Am J Cardiol"},{"key":"2024081413471670300_bib15","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijcard.2014.04.170","article-title":"SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation","volume":"174","author":"Stabile","year":"2014","journal-title":"Int J Cardiol"},{"key":"2024081413471670300_bib16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jcin.2017.04.014","article-title":"Aspirin versus aspirin plus clopidogrel as antithrombotic treatment following transcatheter aortic valve replacement with a balloon-expandable valve: the ARTE (Aspirin versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) randomized clinical trial","volume":"10","author":"Rod\u00e9s-Cabau","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"2024081413471670300_bib17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa1915152","article-title":"Anticoagulation with or without clopidogrel after transcatheter aortic valve implantation","volume":"382","author":"Nijenhuis","year":"2020","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJMoa2017815","article-title":"Aspirin with or without clopidogrel after transcatheter aortic-valve implantation","volume":"383","author":"Brouwer","year":"2020","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib20","first-page":"e009983","article-title":"Randomized trial of aspirin versus warfarin after transcatheter aortic valve replacement in low-risk patients","volume":"14","author":"Rogers","year":"2021","journal-title":"Circ: Cardiovasc Interv"},{"key":"2024081413471670300_bib21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"key":"2024081413471670300_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1161\/CIRCULATIONAHA.122.059512","article-title":"Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR: the ADAPT-TAVR randomized clinical trial","volume":"146","author":"Park","year":"2022","journal-title":"Circulation"},{"key":"2024081413471670300_bib23","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"2024081413471670300_bib24","article-title":"A randomized trial of short-course dual antiplatelet therapy vs. oral anticoagulation to prevent cerebral embolism after transcatheter aortic valve replacement","author":"Diaz","journal-title":"Transcatheter Cardiovascular Therapeutics conference 2019. Available at"},{"key":"2024081413471670300_bib25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjcard.2018.04.006","article-title":"Meta-analysis comparing single versus dual antiplatelet therapy following transcatheter aortic valve implantation","volume":"122","author":"Maes","year":"2018","journal-title":"Am J Cardiol"},{"key":"2024081413471670300_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijcard.2022.05.060","article-title":"Antithrombotic strategies after transcatheter aortic valve implantation: a systematic review and network meta-analysis of randomized controlled trials","volume":"362","author":"Ke","year":"2022","journal-title":"Int J Cardiol"},{"key":"2024081413471670300_bib27","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.cpcardiol.2022.101348","article-title":"Antithrombotic strategy after transcatheter aortic valve replacement: a network meta-analysis","volume":"47","author":"Mahalwar","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"2024081413471670300_bib28","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjcvp\/pvad003","article-title":"Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials","volume":"9","author":"Guedeney","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2024081413471670300_bib29","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/eurheartj\/ehab196","article-title":"Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease","volume":"42","author":"Ten Berg","year":"2021","journal-title":"Eur Heart J"},{"key":"2024081413471670300_bib30","first-page":"e012194","article-title":"Direct oral anticoagulants versus antiplatelet therapy after transcatheter aortic valve replacement: a meta-analysis of randomized trials","volume":"15","author":"Elbadawi","year":"2022","journal-title":"Circ: Cardiovasc Interv"},{"key":"2024081413471670300_bib31","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet North Am Ed"},{"key":"2024081413471670300_bib32","article-title":"Safety profile evaluation of ticagrelor alone compared to a combination of lysine acetylsalicylate-clopidogrel in the context of transcatheter aortic valve implantation (TAVI) (TICTAVI)"},{"key":"2024081413471670300_bib33","article-title":"Anticoagulation versus acetylsalicylic acid after transcatheter aortic valve implantation (ACASA-TAVI)"},{"key":"2024081413471670300_bib34","article-title":"Anticoagulation alone versus anticoagulation and aspirin following transcatheter aortic valve interventions (1:1) (AVATAR)"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvad101\/55974525\/pvad101.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/454\/58818482\/pvad101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/5\/454\/58818482\/pvad101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T13:48:45Z","timestamp":1723643325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/5\/454\/7469485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,11]]},"published-print":{"date-parts":[[2024,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvad101","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2023,12,11]]}}}